Influenza A viruses can cause a highly contagious respiratory illness in humans. Immediately after virus infection the innate immune response is initiated by binding of viral RNA species to RIG-I that leads to activation of IRF3 and NF-κB transcription factors and activation of interferon (IFN) transcription. LGP2 is a member of the RIG-I like receptor (RLR) family and is induced after virus infection. The role of LGP2 in virus infection is controversial: it has been reported to either positively or negatively affect RIG-I mediated signaling. The goal of this study was to determine whether LGP2 has a role during infection with influenza A viruses that have circulated in humans. We focused on two viruses expressing NS1 proteins that differ in their ability to inhibit IRF3 activation and IFN transcription; a H1N1 virus (Tx91) that inhibits IRF3 activation and a H3N2 virus (Ud) that does not. This study revealed that LGP2 has strikingly different roles during infection of mouse embryonic fibroblasts and human cells with these viruses. Specifically, LGP2 has no detectable role in H1N1 virus-infected cells, whereas it downregulates IFN synthesis in H3N2 virus-infected cells. Our results indicate that LGP2 acts as a negative regulator of the IFN response in influenza A viruses that activate IRF3. The NS1 protein also binds the 30kDa-subunit of the cleavage and polyadenylation specificity factor-CPSF30, a protein required for 3′-end processing of cellular pre-mRNAs, thereby inhibiting production of mature IFN-β mRNA. The NS1 proteins of pathogenic 1997 H5N1 viruses lack two highly conserved residues (F103 and M106) that are needed to stabilize the NS1-CPSF30 complex. Instead their NS1 proteins have L at 103 and I at 106, resulting in non-optimal CPSF30 binding in infected cells. We demonstrated that strengthening CPSF30 binding by changing L and I to the consensus residues (F and M respectively) leads to a dramatic (300-fold) increase in lethality of the virus in mice. This increased virulence is associated with faster systemic spread of the virus. Microarray analyses revealed increased cytokine levels in extrapulmonary tissues, particularly the brain. These results highlight the importance of NS1:CPSF30 binding in modulating virulence in H5N1 viruses. / text

Cardiovascular disease, and myocardial infarction (MI) in particular, remains a major burden in the developed world today. In fact, the remodeling process, which follows the initial ischemic episode of MI, is a major determinant of heart failure. Although several key mechanistic pathways involving cell growth and death have been identified, there is limited knowledge surrounding the role of the innate immune response as a positive or negative regulator of cardiac remodeling. Recent data strongly support a role for key regulatory components within the toll-like receptor (TLR) family as potent modulators of cardiac remodeling post-MI. It has been demonstrated that targeted gene knockdown of TLR4, as well as downstream adaptor proteins and kinases, significantly improve cardiac function and overall survival. While the well-known NF-κB transcriptional factor that is downstream to TLR4 signaling has been linked to remodeling, there has been no evidence thus far describing a role of the parallel interferon regulatory factor-3 (IRF3) signaling cascade in any facet of this process. Several key findings suggest that IRFs contribute to both cell growth and apoptosis, thus providing an appealing, and novel target for interrogation. In this thesis I describe how IRF3 contributes to maladaptive remodeling post-MI. In my first set of experiments, I demonstrate that IRF3 is acutely upregulated within the cardiomyocyte following MI and that this response contributes to excessive apoptosis post-MI. A targeted deletion of the IRF3 gene enhances cardiac function, decreases infarct size, and improves survival following MI. In the second set of experiments I demonstrate that IRF3 attenuates angiogenesis at the ischemic border zone by upregulating the expression of thrombospondins. I have shown that IRF3 deficiency, which liberates endogenous anti-angiogenic signals, promotes angiogenesis following ischemic injury. These data suggest that IRF3 is a potent regulator of cardiac remodeling and may be an effective therapeutic target to ameliorate maladaptive cardiac repair post-MI.

Thesis (Ph. D.)--University of Texas Southwestern Medical Center at Dallas, 2006. / Vita. Includes bibliographical references (p. 170-180).

No description available.

Gain-of-function polymorphisms in the gene encoding human interferon regulatory factor-5 (IRF5) are associated with an increase in risk for the development of the autoimmune disease Systemic Lupus Erythematosus (SLE). IRF5 is a transcription factor that participates in the activation of the immune system through its role in both innate and adaptive immune cells. To determine the role of IRF5 in lupus pathogenesis in vivo, we evaluated the effect of Irf5-deficiency in the MRL/lpr mouse lupus model. We find that Irf5-deficient (Irf5-/-) MRL/lpr mice develop much less severe disease than their Irf5-sufficient (Irf5+/+) littermates, demonstrating an important role for IRF5 in disease pathogenesis in vivo. Patients with SLE are at increased risk for the development of atherosclerosis due in large part to poorly-defined lupus-specific risk factors. One such lupus-specific risk factor is thought to be chronic inflammation associated with the autoimmune process. As IRF5 is involved in pro-inflammatory responses we hypothesized that Irf5-deficiency would ameliorate atherosclerosis development in the context of autoimmunity. We therefore examined the role of IRF5 in the gld.apoE-/- mouse model of lupus and lupus-associated atherosclerosis. Irf5-deficiency led to a decrease in splenomegaly, lymphadenopathy, anti-nuclear autoantibody production and the severity of kidney disease. Surprisingly, despite the reduction in systemic autoimmunity, Irf5-deficiency led to a marked increase in the severity of atherosclerosis and to metabolic dysregulation characterized by hyperlipidemia, increased adiposity and insulin-resistance. Bone marrow chimera studies revealed that the pathogenic role of IRF5 in lupus was solely due to its expression in hematopoietic cells. The atheroprotective effect of Irf5 and the suppression of adiposity were found to be due to Irf5 expression in both hematopoietic and non-hematopoietic cells, whereas protection from hyperlipidemia was solely due to the expression of Irf5 in non-hematopoietic cells. Together, our results reveal a role for IRF5 in metabolic homeostasis, as well as in protection against atherosclerosis even in the setting of reduced lupus severity.

No description available.

Opioid receptor-mediated regulation of chemokine receptors is vital for the host immune response, development, and neurological function. Previous studies have demonstrated that the kappa opioid receptor (KOR) activation results in decreased infectivity of human immunodeficiency virus 1 (HIV-1) in human peripheral blood mononuclear cells (PBMCs). We have found this effect is due to down-regulation of the major HIV-1 co-receptors, CCR5 and CXCR4. Using molecular techniques, CCR5 and CXCR4 mRNA levels drop dramatically following KOR activation. To dissect the mechanism involved, we used transcription factor binding arrays and compared control cell extracts to KOR activated cell extracts. We determined that the interferon regulatory factors (IRFs) and signal transducers and activators of transcription (STATs) could be involved in the KOR-mediated repression of CCR5 and CXCR4 transcription and protein expression. Using chemical inhibitors and small interfering RNA (siRNA) molecules, we determined that JAK2, STAT3, and IRF2 are critical members of this signal transduction pathway. The understanding of these particular mechanisms should prove to be beneficial for the development of potential pharmacological agents targeted at HIV-1 binding and infection since virus infection requires expression of the co-receptors CXCR4 and CCR5. Understanding the molecular basis for KOR-induced inhibition of co-receptor expression may provide a basis for the development of KOR agonist-based therapeutics to treat individuals infected with HIV. / Molecular Biology and Genetics

O gene fator regulador de interferon 4 (IRF4), localizado na região cromossômica 6p25- p23, é um membro da família de fatores reguladores de interferon (IRF), um grupo de fatores de transcrição de ligação ao DNA, sendo IRF4 primariamente associado ao desenvolvimento e resposta imune e expresso exclusivamente em células do sistema imunológico e em linhagens melanocíticas. Embora muitos estudos tenham associado IRF4 a diversas condições, como melanoma e leucemia linfocítica crônica, um recente Genome-Wide Association Study (GWAS) identificou que alelos do SNP rs12203592 (intron 4) estão associados com variação fenotípica em relação à presença de sardas, pigmentação da pele, cabelos e olhos. Estudos funcionais realizados em células melanocíticas humanas e de camundongos revelaram que este SNP está diretamente envolvido na regulação da expressão de IRF4, sugerindo uma clara função na pigmentação do melanócito. Apesar destes achados, a diversidade das regiões regulatórias e codificadora de IRF4 não foi até o momento analisada em populações miscigenadas. A fim de avaliar se outros sítios de variação ao longo do gene IRF4 podem estar associados à pigmentação humana, as regiões regulatórias (promotora e 3´UTR) e codificadora (9 exons e regiões intrônicas flanqueadoras, incluindo o SNP rs12203592) foram analisadas por sequenciamento de nova geração em uma amostra miscigenada da população brasileira. A amostra populacional foi composta por 228 indivíduos não aparentados de Ribeirão Preto, estado de São Paulo, Brasil, os quais foram estratificados de acordo com a pigmentação da pele (clara, média e escura), olhos (azul, verde, castanho-claros e castanho-escuros), cabelo (ruivo, loiro-claro, loiroescuro, castanho-claro, castanho-escuro e preto) bem como em relação à presença de sardas e intensidade de cabelos grisalhos. Bibliotecas de DNA foram preparadas utilizando o Sistema de Enriquecimento de Alvo Haloplex (Agilent Technologies) e sequenciadas na plataforma MiSeq (Illumina). Os pacotes de software CutAdapt, BWA and GATK foram utilizados, respectivamente, para trimagem das sequências dos adaptadores, alinhamento e identificação de variantes. Haplótipos e alelos não identificados foram inferidos pelo método PHASE, embora a fase conhecida entre os sítios de variação (obtida pelo GATK) tenha sido levada em consideração. Um total de 105 sítios de variação foram identificados. Apenas dois deles apresentaram frequências genotípicas que não atendem ao esperado pelo equilíbrio de Hardy-Weinberg (EHW). Dezoito destes SNPs apresentaram forte associação a pelo menos uma característica de pigmentação. Entretanto, se a conservadora correção de Bonferroni para múltiplos testes for levada em consideração, apenas duas associações, ambas envolvendo o SNP rs12203592, permanecem significativas: a associação do alelo T com pele clara e olhos azuis. Este resultado está de acordo com estudos prévios, que reportam que o alelo rs12203592*T leva a uma menor ativação de IRF4 e a uma expressão reduzida da tirosinase, resultando em sensibilidade ao sol e olhos azuis. Foi inferido um total de 101 haplótipos, estando a distribuição destes de acordo com o esperado pelo EHW. Quando os haplótipos foram divididos em haplótipos da promotora, codificadora e 3´UTR foram observadas, respectivamente, 17, 29 e 37 diferentes combinações haplotípicas. Várias associações foram identificadas, particularmente envolvendo o haplótipo mais frequente da promotora, os dois haplótipos mais frequentes da codificadora e o haplótipo mais frequente da 3´UTR, todos associados com pele clara, olhos azuis, cabelos castanhos e cabelos grisalhos. Estes resultados sugerem que outras variantes além de rs12203592, quando consideradas em um contexto haplotípico, são associadas com a pigmentação humana. / The Interferon Regulatory Factor 4 (IRF4) gene, located at chromosomal region 6p25- p23, is a member of the interferon regulatory factor (IRF) family, a group of DNAbinding transcription factors, with the IRF4 primarily associated with immune system development and response and expressed exclusively in immune system cells and melanocytic lineages. Although many studies have shown that IRF4 is associated with many human conditions, such as melanoma and chronic lymphocytic leukemia, a recent Genome-Wide Association Study (GWAS) identified that alleles from the SNP rs12203592 (intron 4) is also associated with phenotypic variation regarding presence of freckles, hair, eye and skin pigmentation. Functional studies in human and mice melanin-containing cells revealed that such SNP is directly involved in the regulation of IRF4 expression, suggesting a clear role in melanocyte pigmentation. In spite of these findings, the regulatory and coding IRF4 diversities in admixed populations have not been evaluated so far. In order to verify if other variation sites spread across the IRF4 gene may be associated with human pigmentation, the regulatory (promoter and 3\'UTR regions) and coding (9 exons and flanking intronic regions, including the SNP rs12203592) regions were analyzed by next-generation sequencing procedures in a Brazilian admixed population sample. The population sample was composed of 228 unrelated individuals from the Ribeirão Preto area, São Paulo State, Brazil, which were stratified according to eye (blue, green, hazel, light-brown, and dark-brown), hair (red, blond, dark-blond, light-brown, dark-brown and black) and skin (light, intermediate and dark) pigmentation, as well as regarding the presence of freckles and intensity of hair greying. DNA libraries were prepared using the Haloplex Target Enrichment System (Agilent Technologies) and sequenced at the MiSeq platform (Illumina). CutAdapt, BWA and GATK software packages were used for trimming adaptor sequences, alignment and genotype calling, respectively. Missing alleles and haplotypes were inferred by using the PHASE method, although the known phase between variable sites (obtained by GATK) was taken into account. A total of 105 variation sites were identified. Only two of them presented genotype frequencies that did not fit Hardy- Weinberg equilibrium (HWE) expectations. Eighteen of these SNPs presented strong association with at least one pigmentation feature. However, if the conservative Bonferroni correction for multiple tests is taken into account, only two associations, both of them involving the rs12203592 SNP, remain significant: allele T associated with light skin and blue eyes. This result is in agreement with previous reports that the rs12203592*T allele leads to reduced IRF4 activation and reduced tyrosinase expression, leading to sun sensitivity and blue eyes. A total of 101 different haplotypes were inferred, and haplotype distribution was in agreement to HWE expectations. When haplotypes were subdivided in promoter, coding and 3\'UTR haplotypes, 17, 29 and 37 different haplotypes were observed, respectively. Various associations were identified, particularly involving the most frequent promoter haplotype, the two most frequent coding (only one of them with allele rs12203592*T), and the most frequent 3\'UTR, all of them with light skin, blue eyes, brown hair and hair greying. These results suggest that other variation sites besides rs12203592, when considered in a haplotypic background, are associated with human pigmentation.

<p>The breakdown of self-tolerance is the main driving force behind susceptibility to SLE. When this occurs, T and B cells are activated in an uncontrolled manner and produce autoantibodies against self fragmented DNA, RNA and sometimes other parts of the cell such as cardiolipin, phosphatidylserine, etc.</p><p>The mechanism behind the breakdown of self-tolerance may be genetic factors that are triggered by environmental factors. SLE is not caused by a single gene, but by many genes, and is thus a polygenic disease. So far only a few genes have been found to be associated with SLE including PDCD1, FcγRs, and PTPN22. The main aim of my thesis is to find susceptibility genes responsible for SLE.</p><p>Recently, a gene called IRF5 was found to be associated with SLE. In paper one, we performed a thorough study and confirmed its association to SLE. In addition, we found a few other SNPs in the gene that were associated to the disease. Among them, SNP rs2004640 is very strongly associated and was found to affect the splicing of the gene. Another SNP, rs2280714, correlated with overexpression of the gene, although SNP rs10954213 was much more highly correlated with expression adding to this, in paper two we found a few other SNPs that were associated to SLE and played crucial roles in gene function. An indel in exon 6, though not associated by itself, regulated which isoforms were expressed. Individuals with 2 repeats expressed isoforms V1 and V4, while individuals with 4 repeats expressed isoforms V5 and V6. SNP rs2070197 was also very strongly associated, but did not have a functional role. In paper three, the same polymorphisms were studied in a Mexican population, which showed an even stronger association when compared to a European population.</p><p>It is known that autoimmune diseases share susceptibility genes, therefore we wanted to see if the IRF5 gene is associated with any other autoimmune diseases. In papers four and five, we tested its association to RA (using three sets of patients and controls from Sweden, Argentina and Spain) and psoriasis (using a set of patients and controls from Sweden). Association was not found in either of the diseases. Therefore, we believe that this association may be SLE-specific.</p>

The breakdown of self-tolerance is the main driving force behind susceptibility to SLE. When this occurs, T and B cells are activated in an uncontrolled manner and produce autoantibodies against self fragmented DNA, RNA and sometimes other parts of the cell such as cardiolipin, phosphatidylserine, etc. The mechanism behind the breakdown of self-tolerance may be genetic factors that are triggered by environmental factors. SLE is not caused by a single gene, but by many genes, and is thus a polygenic disease. So far only a few genes have been found to be associated with SLE including PDCD1, FcγRs, and PTPN22. The main aim of my thesis is to find susceptibility genes responsible for SLE. Recently, a gene called IRF5 was found to be associated with SLE. In paper one, we performed a thorough study and confirmed its association to SLE. In addition, we found a few other SNPs in the gene that were associated to the disease. Among them, SNP rs2004640 is very strongly associated and was found to affect the splicing of the gene. Another SNP, rs2280714, correlated with overexpression of the gene, although SNP rs10954213 was much more highly correlated with expression adding to this, in paper two we found a few other SNPs that were associated to SLE and played crucial roles in gene function. An indel in exon 6, though not associated by itself, regulated which isoforms were expressed. Individuals with 2 repeats expressed isoforms V1 and V4, while individuals with 4 repeats expressed isoforms V5 and V6. SNP rs2070197 was also very strongly associated, but did not have a functional role. In paper three, the same polymorphisms were studied in a Mexican population, which showed an even stronger association when compared to a European population. It is known that autoimmune diseases share susceptibility genes, therefore we wanted to see if the IRF5 gene is associated with any other autoimmune diseases. In papers four and five, we tested its association to RA (using three sets of patients and controls from Sweden, Argentina and Spain) and psoriasis (using a set of patients and controls from Sweden). Association was not found in either of the diseases. Therefore, we believe that this association may be SLE-specific.